Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 180,855 | 156,797 | 137,785 | 122,536 | 112,214 |
| Cost of Goods | 20,257 | 18,603 | 17,868 | 17,896 | 20,109 |
| Gross Profit | 160,598 | 138,194 | 119,917 | 104,640 | 92,105 |
| Operating Expenses | 136,834 | 118,637 | 107,513 | 124,835 | 101,872 |
| Operating Income | 24,021 | 20,160 | 13,272 | -19,299 | -9,658 |
| Other Income | 3,136 | 2,717 | 2,293 | 2,320 | 2,457 |
| Pre-tax Income | 27,157 | 22,877 | 15,565 | -16,979 | -7,201 |
| Income Tax | 8,722 | 5,045 | 7,026 | -8,091 | 5,492 |
| Net Income Continuous | 18,435 | 17,832 | 8,539 | -8,888 | -12,693 |
| Net Income | $18,435 | $17,832 | $8,539 | $-8,888 | $-12,693 |
| EPS Basic Total Ops | 0.25 | 0.24 | 0.12 | -0.11 | -0.18 |
| EPS Basic Continuous Ops | 0.25 | 0.24 | 0.12 | -0.12 | -0.18 |
| EPS Diluted Total Ops | 0.23 | 0.23 | 0.11 | -0.11 | -0.18 |
| EPS Diluted Continuous Ops | 0.23 | 0.23 | 0.11 | -0.12 | -0.18 |
| EPS Diluted Before Non-Recurring Items | 0.23 | 0.23 | 0.11 | -0.12 | -0.18 |
| EBITDA(a) | $24,405 | $20,518 | $13,617 | $-18,899 | $-9,259 |